Access the full text.
Sign up today, get DeepDyve free for 14 days.
Joacim Elmén, M. Lindow, Sylvia Schütz, M. Lawrence, A. Petri, S. Obad, M. Lindholm, Maj Hedtjärn, H. Hansen, U. Berger, S. Gullans, P. Kearney, P. Sarnow, E. Straarup, S. Kauppinen (2008)
LNA-mediated microRNA silencing in non-human primatesNature, 452
B. Lewis, C. Burge, D. Bartel (2005)
Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 120
D. Bartel (2004)
MicroRNAs Genomics, Biogenesis, Mechanism, and FunctionCell, 116
M. Kano, N. Seki, N. Kikkawa, L. Fujimura, Isamu Hoshino, Y. Akutsu, T. Chiyomaru, H. Enokida, M. Nakagawa, H. Matsubara (2010)
miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinomaInternational Journal of Cancer, 127
P. Oldenborg, H. Gresham, Yongmei Chen, S. Izui, F. Lindberg (2002)
Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice.Blood, 99 10
S. Jaiswal, M. Chao, R. Majeti, I. Weissman (2010)
Macrophages as mediators of tumor immunosurveillance.Trends in immunology, 31 6
Makoto Nagahara, K. Mimori, A. Kataoka, H. Ishii, F. Tanaka, Tsuyoshi Nakagawa, Takanobu Sato, Shinji Ono, K. Sugihara, M. Mori (2010)
Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer PatientsClinical Cancer Research, 16
A. Junker, M. Krumbholz, S. Eisele, Hema Mohan, Florian Augstein, R. Bittner, H. Lassmann, H. Wekerle, R. Hohlfeld, E. Meinl (2009)
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47.Brain : a journal of neurology, 132 Pt 12
D. Bartel (2009)
MicroRNAs: Target Recognition and Regulatory FunctionsCell, 136
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
Hui Wang, M. Madariaga, Shumei Wang, N. Rooijen, P. Oldenborg, Yong-Guang Yang (2007)
Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cellsProceedings of the National Academy of Sciences, 104
K. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti, Howard Chang, M. Rijn, L. Shortliffe, I. Weissman (2009)
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences, 106
N. Nohata, T. Hanazawa, N. Kikkawa, Muradil Mutallip, L. Fujimura, H. Yoshino, Kazumori Kawakami, T. Chiyomaru, H. Enokida, M. Nakagawa, Y. Okamoto, N. Seki (2010)
Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma.International journal of oncology, 38 1
H. Nagata, T. Arai, Yusuke Soejima, Hidekazu Suzuki, H. Ishii, T. Hibi (2004)
Limited Capability of Regional Lymph Nodes to Eradicate Metastatic Cancer CellsCancer Research, 64
V. Gebski, B. Burmeister, B. Smithers, K. Foo, J. Zalcberg, J. Simes (2007)
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.The Lancet. Oncology, 8 3
P. Oldenborg, A. Zheleznyak, Yi Fang, C. Lagenaur, H. Gresham, F. Lindberg (2000)
Role of CD47 as a marker of self on red blood cells.Science, 288 5473
J. Tepper, M. Krasna, D. Niedzwiecki, D. Hollis, C. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, R. Mayer (2008)
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 7
Yong Guo, Zhaoli Chen, Liang Zhang, F. Zhou, S. Shi, Xiaoli Feng, Baozhong Li, Xin Meng, Xi Ma, Mingyong Luo, K. Shao, Ning Li, B. Qiu, K. Mitchelson, Jing Cheng, Jie He (2008)
Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma.Cancer research, 68 1
H. Okazawa, S. Motegi, Naoko Ohyama, H. Ohnishi, Takeshi Tomizawa, Y. Kaneko, P. Oldenborg, O. Ishikawa, T. Matozaki (2005)
Negative Regulation of Phagocytosis in Macrophages by the CD47-SHPS-1 System1The Journal of Immunology, 174
K. Asano, Ami Nabeyama, Yasunobu Miyake, Chunhong Qiu, A. Kurita, M. Tomura, O. Kanagawa, S. Fujii, Masato Tanaka (2011)
CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens.Immunity, 34 1
M. Shinohara, Naoko Ohyama, Yoji Murata, H. Okazawa, H. Ohnishi, O. Ishikawa, T. Matozaki (2006)
CD47 regulation of epithelial cell spreading and migration, and its signal transductionCancer Science, 97
R. Malthaner, R. Wong, R. Rumble, L. Zuraw, Members Care (2004)
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysisBMC Medicine, 2
T. Wong, Xiao‐bing Liu, B. Wong, R. Ng, A. Yuen, W. Wei (2008)
Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of TongueClinical Cancer Research, 14
T. Chiyomaru, H. Enokida, S. Tatarano, K. Kawahara, Y. Uchida, K. Nishiyama, L. Fujimura, N. Kikkawa, N. Seki, M. Nakagawa (2010)
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancerBritish Journal of Cancer, 102
Y. Hashimoto, Tetsuo Ito, H. Inoue, T. Okumura, E. Tanaka, S. Tsunoda, M. Higashiyama, G. Watanabe, M. Imamura, Y. Shimada (2005)
Prognostic Significance of Fascin Overexpression in Human Esophageal Squamous Cell CarcinomaClinical Cancer Research, 11
T. Berg, C. Schoot (2008)
Innate immune ‘self’ recognition: a role for CD47–SIRPα interactions in hematopoietic stem cell transplantationTrends in Immunology, 29
M. Chao, Ash Alizadeh, Chad Tang, J. Myklebust, B. Varghese, S. Gill, Max Jan, Adriel Cha, Charles Chan, Brent Tan, Christopher Park, Feifei Zhao, H. Kohrt, R. Malumbres, J. Briones, R. Gascoyne, I. Lossos, R. Levy, I. Weissman, R. Majeti (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 142
R. Majeti, M. Chao, Ash Alizadeh, W. Pang, S. Jaiswal, Kenneth Gibbs, N. Rooijen, I. Weissman (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 138
P. Silvestri, C. Russo, S. Rigattieri, S. Fedele, D. Todaro, G. Ferraiuolo, G. Altamura, P. Loschiavo (2009)
MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets.Recent patents on cardiovascular drug discovery, 4 2
E. Missiaglia, Christopher Shepherd, S. Patel, K. Thway, G. Pierron, K. Pritchard-Jones, M. Renard, R. Sciot, P. Rao, O. Oberlin, O. Delattre, O. Delattre, J. Shipley (2010)
MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomasBritish Journal of Cancer, 102
H. Kuwano, M. Nakajima, T. Miyazaki, H. Kato (2003)
Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 9 1
H. Soifer, J. Rossi, P. Sætrom (2007)
MicroRNAs in Disease and Potential Therapeutic Applications.Molecular therapy : the journal of the American Society of Gene Therapy, 15 12
E. Bandrés, E. Cubedo, X. Agirre, R. Malumbres, R. Zárate, N. Ramirez, A. Abajo, A. Navarro, I. Moreno, M. Monzó, J. García-Foncillas (2006)
Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissuesMolecular Cancer, 5
S. Volinia, G. Calin, Chang-gong Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C. Harris, C. Croce (2006)
A microRNA expression signature of human solid tumors defines cancer gene targetsProceedings of the National Academy of Sciences of the United States of America, 103
Jun Lu, G. Getz, E. Miska, Ezequiel Alvarez-Saavedra, J. Lamb, David Peck, A. Sweet-Cordero, B. Ebert, Raymond Mak, A. Ferrando, J. Downing, T. Jacks, H. Horvitz, T. Golub (2005)
MicroRNA expression profiles classify human cancersNature, 435
G. Childs, M. Fazzari, G. Kung, N. Kawachi, M. Brandwein-Gensler, M. McLemore, Quan Chen, R. Burk, Richard Smith, M. Prystowsky, T. Belbin, N. Schlecht (2009)
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.The American journal of pathology, 174 3
T. Song, W. Xia, Ningsheng Shao, Xu Zhang, Chun-yang Wang, Yiguang Wu, Jun Dong, W. Cai, Hong-zhao Li (2010)
Differential miRNA expression profiles in bladder urothelial carcinomas.Asian Pacific journal of cancer prevention : APJCP, 11 4
P. Rao, E. Missiaglia, L. Shields, Greg Hyde, Bingbing Yuan, Christopher Shepherd, J. Shipley, H. Lodish (2010)
Distinct roles for miR‐1 and miR‐133a in the proliferation and differentiation of rhabdomyosarcoma cellsThe FASEB Journal, 24
M. Chao, Ash Alizadeh, Chad Tang, Max Jan, R. Weissman-Tsukamoto, Feifei Zhao, Christopher Park, I. Weissman, R. Majeti (2011)
Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.Cancer research, 71 4
M. Valencia-Sanchez, Jidong Liu, G. Hannon, R. Parker (2006)
Control of translation and mRNA degradation by miRNAs and siRNAs.Genes & development, 20 5
Enzinger (2003)
Esophageal cancerN Engl J Med, 349
CD47 inhibits phagocytosis and its overexpression is correlated with poor prognosis in patients with several types of cancer. It has also been reported that CD47 expression in multiple sclerosis is regulated by microRNAs. However, the regulatory mechanism of CD47 in cancer tissues has not been yet clarified. Re-analysis of a public microarray database revealed that miR-133a is downregulated in esophageal squamous cell carcinoma (ESCC). Moreover, in silico algorithms predicted that miR-133a is a regulator of CD47. The purpose of this study was to clarify the clinical significance of CD47 and its regulatory mechanism by miR-133a in ESCC. Quantitative real-time RT-PCR was used to evaluate CD47 and miR-133a expression in 102 cases of curative resected ESCC and adjacent non-cancerous tissue. The regulation of CD47 by miR-133a was examined with precursor miR-133a-transfected cells. A mouse xenograft model was used to investigate the ability of miR-133a to suppress tumor progression. High expression levels of CD47 were associated with lymph node metastasis (P=0.049). Multivariate analysis showed that CD47 expression was an independent prognostic factor (P=0.045). miR-133a expression was significantly lower in cancer tissues compared to adjacent non-cancerous tissues (P<0.001). In vitro assays showed that miR-133a is a direct regulator of CD47. miR‑133a significantly inhibited tumorigenesis and growth in vivo. CD47 expression is a novel prognostic marker in ESCC that is directly inhibited by the miR-133a tumor suppressor. This correlation could provide new insight into the mechanism of cancer progression and a promising candidate for target therapy in ESCC.
Oncology Reports – Spandidos Publications
Published: Aug 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.